Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Deferred Taxes (2023 - 2024)

Xeris Biopharma Holdings (XERS) has disclosed Deferred Taxes for 2 consecutive years, with -$3.3 million as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Deferred Taxes fell 592.44% year-over-year to -$3.3 million, compared with a TTM value of -$3.3 million through Jun 2025, down 789.63%, and an annual FY2024 reading of -$2.3 million, down 81.59% over the prior year.
  • Deferred Taxes was -$3.3 million for Q3 2024 at Xeris Biopharma Holdings, down from $749000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $749000.0 in Q2 2024 and bottomed at -$3.3 million in Q3 2024.